Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

n its current fiscal year, which ends

on March 31, 2009.

ITMN-191 Program in HCV:

-- Assuming submitted abstracts will be accepted, InterMune expects to

present several abstracts on ITMN-191 at AASLD, scheduled for

October 31 - November 4 in San Francisco. These abstracts pertain

to various clinical studies on ITMN-191 and in-vitro studies of

ITMN-191 in combination with other direct antiviral compounds.

-- InterMune expects to announce top-line results from the currently

running 14-day study of ITMN-191 in combination with Pegasys and

ribavirin in the fourth quarter of 2008.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EDT to discuss its financial results for the second quarter 2008, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 57393097. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 57393097. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfo
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
(Date:12/22/2014)... Dec. 22, 2014 GenomeDx Biosciences today announced ... Cancer Classifier, a genomic test for prostate cancer, was ... men managed by radical prostatectomy without adjuvant therapy. Although ... relatively uncommon, using tumor genomics to identify these men ... is an important advance. The study has been ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Fertility Associates ... Donor Egg Bank USA , a network of more ... Through this partnership, patients have fast access to a ... vitro fertilization, IVF . Fertility Associates of Memphis is ... this fertility treatment option. , Dr. William Kutteh ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... 1, 2012 Unigene Laboratories, Inc. (OTCBB: ... Drug Delivery Partnerships™ ("DDP") Innovation Award in the Industry ... advances in the oral delivery of peptides.  ... and selected by conference attendees, including leading scientists, pharmaceutical ...
...  Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that ... been awarded a Japanese Patent centering on its ... A number of products developed with this technology ... to secure the novel Antigen Express vaccine technology ...
... MINNEAPOLIS, February 1, 2012 Alchem International ... The sales and marketing office will be spearheaded by ... This office will cater to the rapidly growing demand ... their purified derivatives for the supplement, pharmaceutical and cosmetic ...
Cached Biology Technology:Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award 2Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award 3Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award 4Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award 5Generex Announces Patent Award for its Core Vaccine Technologies in Japan 2Generex Announces Patent Award for its Core Vaccine Technologies in Japan 3Generex Announces Patent Award for its Core Vaccine Technologies in Japan 4Alchem International Opens Sales and Marketing Office in the U.S. 2
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 ... and collaboration catalyst that provides the connective tissue that ... by enabling them to easily share client-level information; earned ... Foundation to expand to organizations serving seniors aging in ... San Diego" partner on December 11 th 4-6p. ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:11/21/2014)... Nov. 20, 2014 Strict laws against distracted ... piloting the North American and European automotive sector towards ... gesture recognition systems that are intuitive and able to ... the industry. New analysis from Frost ... Market in Europe and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... Optiqua Technologies Pte Ltd is collaborating with Nanyang ... in biomolecular sciences and sensor technology. Optiqua, ... provides the international water industry with innovative products ... detection of contaminants in water. The sensor technology ...
... Oregon Health & Science University Doernbecher Children,s Hospital have defined ... sarcoma. In a study published today as the Featured Article ... childhood and adult sarcomas are linked in their biology, mutations ... findings may lead to non-chemotherapy medicines that can inhibit "molecular ...
... paper published today in PNAS, scientists from the European ... insights into the workings of enzymes from a group ... that causes tuberculosis. The new findings present possible new ... but leave other microorganisms, which are beneficial to us, ...
Cached Biology News:Optiqua-NTU partnership to develop next-generation sensor technology 2Scientists discover cell of origin for childhood muscle cancer 22 in 1: Multi-tasking protein provides new approaches for anti-tuberculosis drugs 2
...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Experion StdSens chips are the microfluidic chips used to perform standard-sensitivity RNA analysis (nanogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to...
...
Biology Products: